Perrigo Reinstates Executive Severance Policy Amid CEO Transition
TipRanks (Mon, 6-Jul 5:20 PM ET)
Perrigo Announces Appointment of Two New Independent Directors to Board
PRNewswire (Tue, 30-Jun 4:26 PM ET)
PRGO Leadership Shake-Up: Board Reaffirms Strategy and 2026 Outlook Amid Sudden CEO Change
Market Chameleon (Tue, 9-Jun 3:33 AM ET)
Perrigo Announces Leadership Transition
PRNewswire (Mon, 8-Jun 4:19 PM ET)
Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
PRNewswire (Tue, 26-May 8:32 AM ET)
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
PRNewswire (Wed, 6-May 5:20 PM ET)
Perrigo Completes Divestiture of Dermacosmetics Business
PRNewswire (Thu, 30-Apr 4:30 PM ET)
Perrigo Announces Quarterly Dividend
PRNewswire (Wed, 29-Apr 8:57 AM ET)
Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026
PRNewswire (Wed, 22-Apr 8:30 AM ET)
Perrigo CEO to Present Strategic Vision at UBS Global Consumer and Retail Conference
Market Chameleon (Wed, 4-Mar 2:08 AM ET)
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Perrigo Company PLC trades on the NYSE stock market under the symbol PRGO.
As of July 8, 2026, PRGO stock price declined to $10.88 with 187,954 million shares trading.
PRGO has a beta of 2.24, meaning it tends to be more sensitive to market movements. PRGO has a correlation of 0.22 to the broad based SPY ETF.
PRGO has a market cap of $1.51 billion. This is considered a Small Cap stock.
Last quarter Perrigo Company PLC reported $939 million in Revenue and $.43 earnings per share. This fell short of revenue expectation by $-86 million and exceeded earnings estimates by $.10.
In the last 3 years, PRGO traded as high as $40.28 and as low as $9.23.
The top ETF exchange traded funds that PRGO belongs to (by Net Assets): IJR, VTI, PEY, IWM, VB.
PRGO has underperformed the market in the last year with a return of -55.0%, while the SPY ETF gained +21.0%. In the last 3 month period, PRGO fell short of the market, returning +5.8%, while SPY returned +13.1%. However, in the most recent 2 weeks PRGO has outperformed the stock market by returning +14.6%, while SPY returned +1.4%.
PRGO support price is $10.76 and resistance is $11.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRGO shares will trade within this expected range on the day.
